Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis

Company Overview

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $2.57 to $2.76
• 50-Day Range: $2.31 to $3.92
• 52-Week Range: $2.21 to $12.00
• Volume: 57,871 shs
• Average Volume: 166,835 shs
• Market Capitalization: $3.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Lipella Pharmaceuticals Stock Analysis - MarketRank™

Lipella Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lipella Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lipella Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipella Pharmaceuticals is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipella Pharmaceuticals is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipella Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.06% of the float of Lipella Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipella Pharmaceuticals has recently decreased by 35.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipella Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Lipella Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.06% of the float of Lipella Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipella Pharmaceuticals has recently decreased by 35.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Lipella Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Lipella Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lipella Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.11% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LIPO Stock Analysis - Frequently Asked Questions

How have LIPO shares performed this year?

Lipella Pharmaceuticals' stock was trading at $8.16 at the start of the year. Since then, LIPO stock has decreased by 68.0% and is now trading at $2.61.
View the best growth stocks for 2024 here.

When did Lipella Pharmaceuticals' stock split?

Lipella Pharmaceuticals shares reverse split on the morning of Friday, November 8th 2024. The 1-8 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did Lipella Pharmaceuticals IPO?

Lipella Pharmaceuticals (LIPO) raised $7 million in an IPO on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share.

How do I buy shares of Lipella Pharmaceuticals?

Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lipella Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), MSP Recovery (LIFW), NVIDIA (NVDA), Processa Pharmaceuticals (PCSA), Energy Transfer (ET) and Labor Smart (LTNC).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIPO
• CUSIP: N/A
• CIK: 1347242
• Web: lipella.com
• Phone: 412-901-0315
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +513.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,620,000.00
• Net Margins: -882.82%
• Pretax Margin: -882.61%
• Return on Equity: -192.33%
• Return on Assets: -154.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.97
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $483,533.00
• Price / Sales: 6.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 1,209,000
• Free Float: 821,000
• Market Cap: $3.16 million
• Optionable: Not Optionable
• Beta: 0.38